摘要
目的分析多西他赛联合伊立替康对卵巢癌患者血清中Th1/Th2类细胞因子水平的影响。方法选取丽水市中心医院2017年6月至2019年6月收治的96例卵巢癌患者作为研究对象。根据随机数字表法分为研究组(n=48)和对照组(n=48)。对照组采用多西他赛治疗,研究组采用西他赛联合伊立替康治疗。观察两组患者肿瘤疾病缓解效果,检测两组患者化疗前后外周血单核细胞(PBMC)Th1/Th2类细胞因子水平。结果研究组患者临床治疗效果优于对照组,差异具有统计学意义(P<0.05);治疗后,研究组患者Th1类细胞因子水平高于对照组患者,Th2类细胞因子水平低于对照组患者,差异均具有统计学意义(均P<0.05);两组患者用药后不良反应发生情况比较,差异无统计学意义(P>0.05)。结论多西他赛联合伊立替康治疗卵巢癌患者,可有效调控Th1/Th2类细胞因子水平,控制恶性肿瘤疾病发展,提高临床干预效果,且联合用药后并不会诱发严重不良反应,具有较高安全性。
Objective To analyze the effect of Docetaxel combined with Irinotecan on the expression of Th1 and Th2 cytokines in ovarian cancer patients.Methods A total of 96 patients with ovarian cancer admitted to Central Hospital of Lishui City from June 2017 to June 2019 were selected as study subjects and divided into study group(n=48)and control group(n=48)according to the random number table method.The control group was treated with Docetaxel,while the control group was treated with Docetaxel combined with Irinotecan.The remission effect of tumor diseases in the two groups was observed,and Th1/Th2 cytokine levels in peripheral blood mononuclear cells(PBMC)of the two groups were detected before and after chemotherapy.Results The therapeutic treatment effect of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the level of Th1 cytokines in the study group was higher than that in the control group,while the level of Th2 cytokines in the study group was lower than that in the control group,with statistically significant differences(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Docetaxel combined with Irinotecan in the treatment of ovarian cancer patients can effectively regulate the level of Th1/Th2 cytokines,control the development of malignant tumor,and improve the clinical intervention effect.In addition,the combined treatment will not induce serious adverse reactions,showing a relatively high safety.
作者
谢侣真
雷刘燕
赵楚楚
XIE Lyuzhen;LEI Liuyan;ZHAO Chuchu(Department of Obstetrics and Gynecology,Central Hospital of Lishui City,Lishui 323000,Zhejiang,China)
出处
《中国性科学》
2020年第10期43-46,共4页
Chinese Journal of Human Sexuality
